Drug Profile
Blisibimod - Anthera Pharmaceuticals
Alternative Names: A-623; AMG-623; BlisibimodLatest Information Update: 19 Feb 2021
Price :
$50
*
At a glance
- Originator Amgen
- Developer Anthera Pharmaceuticals
- Class Immunotherapies; Recombinant fusion proteins
- Mechanism of Action B cell activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; IgA nephropathy; Systemic lupus erythematosus
Most Recent Events
- 02 May 2018 Anthera Pharmaceuticals has patent protection for blisibimod in USA and Europe
- 31 Mar 2018 Suspended - Phase-II for IgA nephropathy (Combination therapy, Treatment-experienced) in Spain, Sweden, Hungary, Italy, United Kingdom, Germany, Czech Republic, Thailand, Taiwan, Singapore, South Korea, Philippines, Malaysia, Hong Kong (SC)
- 31 Mar 2018 Suspended - Phase-II for Systemic lupus erythematosus in Peru, Chile, Argentina, USA (SC)